Molbio Diagnostics Eyes ₹200 Crore for Growth Amid IPO Launch

Molbio Diagnostics, a notable player in the molecular diagnostics sector, is preparing to enter the public market with an initial public offering (IPO) aimed at raising ₹200 crore. The funds are earmarked for capital expenditures to bolster the company's manufacturing capabilities and expand its product offerings. Additionally, the company plans to reduce its promoter stake by generating ₹740 crore through an offer for sale.

Expanding Global Footprint

With six manufacturing sites across India, Molbio Diagnostics serves a vast international clientele spanning over 90 countries. Its products are widely used in government health programs, diagnostic laboratories, hospitals, and international healthcare organizations. A significant portion of its revenue, over 70%, is driven by the sales of its tuberculosis diagnostic test kits, highlighting the company's focus on infectious disease diagnostics.

Financial Performance and Market Position

Molbio has reported substantial financial growth, with revenue from operations increasing by 31.5% annually to reach ₹1,445.7 crore between FY24 and FY26. Net profit during this period also saw a robust 40.2% rise, amounting to ₹164.1 crore. The company's EBITDA grew by 33.2% to ₹328.2 crore, with the EBITDA margin improving to 22.6% in FY26 from 22% in FY24.

The company's valuation demands a price-earnings multiple of up to 57, a figure that stands competitive when compared to other Indian healthcare diagnostics and medical device firms. These include Poly Medicure, Dr. Lal PathLabs, Metropolis Healthcare, and Vijaya Diagnostic Centre, which trade at P/E multiples ranging from 54 to 81.

Innovative Diagnostic Solutions

Founded in 2000, Molbio Diagnostics has carved out a niche in the research, development, and manufacturing of diagnostic solutions for both infectious and non-communicable diseases. The company’s flagship product, the 'Truenat' platform, is a portable diagnostic system capable of delivering accurate test results within an hour, particularly beneficial in resource-limited settings. Molbio offers molecular testing solutions for over 30 diseases through 43 diagnostic assays, and extends its services to radiology, digital pathology, and breast health screening through its subsidiaries and strategic collaborations.

With its strong financial performance and innovative diagnostic solutions, Molbio Diagnostics' IPO presents a potentially attractive opportunity for high-risk investors looking for long-term growth in the healthcare sector.